|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.01.26 - 10:45
|
GSK: Erfolg in Hepatitis B – wird Gilead nun abgehängt? (Sharedeals)
|
|
|
GlaxoSmithKline hat positive Ergebnisse aus den beiden entscheidenden Phase-3-Studien seines experimentellen Medikaments Bepirovirsen zur Behandlung von chronischer Hepatitis B vorgelegt. Noch im laufenden Quartal sollen global entsprechende Zulassungsanträge folgen. Das setzt Virologie-Riesen wie Gilead unter Druck. Die Zulassungsstudien in über 1.800 Patienten haben ihre wichtigsten Wirksamkeitsziele erreicht, was die Hoffnung auf eine funktionelle Heilung der […]
The post GSK: Erfolg in Hepatitis B – wird Gilead nun abgehängt? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.12.25 - 13:03
|
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration (Business Wire)
|
|
|
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”).
“We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “This marks the third and most significant portfolio transaction for Repare this year.”
Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities.
On...
|
|
|
|
|
|
|
|
|
|
|
20.12.25 - 09:12
|
Trump strikes deal with US drugmakers to cut Medicaid medicine costs (The Guardian)
|
|
|
Officials pledge 'massive savings' as companies agree to offer drugs at prices paid in other wealthy countriesDonald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche's US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on. Continue reading......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
